Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

• ClinicalTrials.gov Identifier: NCT03719664
• Recruitment Status: Recruiting
• First Posted: October 25, 2018
• Last Update Posted: September 29, 2021
• Sponsor: Frontier Biotechnologies Inc.
• Information provided by (Responsible Party): Frontier Biotechnologies Inc.

Study Description

Brief Summary:

The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage, safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.

Condition or disease	Intervention/treatment	Phase
HIV-1-infection	Drug: Albuvirtide; Drug: 3BNC117; Drug: Baseline ART	Phase 2

Detailed Description:

This is a three-part, multicenter study that will enroll a total of 80 eligible, HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy. The study will be conducted in three parts.

Part 1 and Part 2 are the dose-ranging portions of the study. In Part 1, 30 eligible subjects will be randomized in a 1:1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 or continue on the existing ART regimen under one of the three cohorts as follows:

• Cohort 1: albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
• Cohort 2: albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
• Control Arm 1: Subjects continuing on baseline ART

In Part 2 of the study, 20 eligible subjects will be randomized in a 1:1 ratio to receive 16 weeks of combination treatment with albuvirtide and 3BNC117 under one of the two cohorts as follows:

• Cohort 3: albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
• Cohort 4: albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks

Part 3 of this study will enroll an additional 30 subjects in a 2:1 ratio to receive up to 28 weeks of combination treatment with optimal dose of albuvirtide and 3BNC117 or continue on the existing ART regimen as follows:

• Optimal Dose: albuvirtide and 3BNC11 every 2 or 4 weeks
• Control Arm 2: Subjects continuing on baseline ART All consenting patients, in Cohort 1 and 2 (Part 1) and Cohort 3 and 4 (Part 2) of the study, will be shifted from daily oral combination antiretroviral regimen to an intravenous infusion of ABT and 3BNC117. The total treatmentduration with the ABT and 3BNC117 combination regimen will be up to 16 weeks (for Part 1 and Part 2) or 28 weeks (for Part 3) with a two week overlap of the baseline oral antiretroviral regimen and the ABT-3BNC117 combination regimen at the beginning of the study treatment and at the end of the treatment phase in subjects who do not experience virologic rebound. During the two week overlap of baseline oral antiretrovirals and ABT-3BNC117 combination regimen at the beginning of the study treatment, subject will receive weekly doses of ABT and 3BNC117 as intravenous infusions. Beyond the overlap period, subjects in Cohort 1 will receive study treatments every two weeks and subjects in Cohort 2, 3, and 4 will receive study treatments every four weeks.

Study participants will be monitored for viral rebound every two weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virologic rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive blood draws.

Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Multicenter, Three-part Study to Establish the Dosage, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects With HIV-1 Infection
• Actual Study Start Date: December 17, 2018
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: December 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1: albuvirtide & 3BNC117; albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks	Drug: Albuvirtide; Intravenous infusion of Albuvirtide; Other Name: Fusion inhibitor; Drug: 3BNC117; Intravenous infusion of 3BNC117; Other Name: Monoclonal antibody
Experimental: Cohort 2: albuvirtide & 3BNC117; albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks	Drug: Albuvirtide; Intravenous infusion of Albuvirtide; Other Name: Fusion inhibitor; Drug: 3BNC117; Intravenous infusion of 3BNC117; Other Name: Monoclonal antibody
Active Comparator: Control Arm 1: Baseline ART; Subjects continuing on baseline ART	Drug: Baseline ART; Subjects continuing on baseline ART; Other Name: ART
Experimental: Cohort 3: albuvirtide & 3BNC117; albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks	Drug: Albuvirtide; Intravenous infusion of Albuvirtide; Other Name: Fusion inhibitor; Drug: 3BNC117; Intravenous infusion of 3BNC117; Other Name: Monoclonal antibody
Experimental: Cohort 4: albuvirtide & 3BNC117; albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks	Drug: Albuvirtide; Intravenous infusion of Albuvirtide; Other Name: Fusion inhibitor; Drug: 3BNC117; Intravenous infusion of 3BNC117; Other Name: Monoclonal antibody
Experimental: Optimal Dose: albuvirtide & 3BNC117; albuvirtide and 3BNC117 every 2 or 4 weeks	Drug: Albuvirtide; Intravenous infusion of Albuvirtide; Other Name: Fusion inhibitor; Drug: 3BNC117; Intravenous infusion of 3BNC117; Other Name: Monoclonal antibody
Active Comparator: Control Arm 2: Baseline ART; Subjects continuing on baseline ART	Drug: Baseline ART; Subjects continuing on baseline ART; Other Name: ART

Outcome Measures

Primary Outcome Measures :

1. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 3 of the study. [ Time Frame: 28 weeks in Part 3 ]

Secondary Outcome Measures :

1. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 1 of the study [ Time Frame: 16 weeks in Part 1 ]
2. Proportion of participants with HIV-1 RNA < 50 copies/mL at the end of treatment phase in Part 2 of the study [ Time Frame: 16 weeks in Part 2 ]
3. Time to virologic rebound after discontinuation of baseline ART regimen [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
   Note: Virologic rebound is defined as two consecutive HIV-1 RNA levels of > 200 copies/ml.
4. Proportion of participants achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
5. Time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
6. Mean change in HIV-1 RNA, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
7. Mean change in CD4 cell count, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
8. Mean change in CD4:CD8 ratio, at each visit within the treatment phase [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
9. Emergence of new resistance mutations to antiretroviral drugs as evaluated by GenoSure Archive or PhenoSense GT Assay [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]
10. Measurement of treatment adherence to the ABT and 3BNC117 combination regimen [ Time Frame: 16 weeks in Part 1 and part 2, 28 weeks in part 3 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Potential subjects are required to meet all of the following criteria for enrollment into the study.

  1. HIV-1 seropositive;
  2. Males and females, age ≥18 years;
  3. Receiving oral combination antiretroviral therapy for last 24 weeks;
  4. No change in antiretroviral regimen within last 4 weeks prior to Screening Visit and in-between Screening Visit and First Treatment Visit with an exception that subjects on NNRTI-containing regimens will be allowed to switch to protease inhibitor- or integrase strand transferase inhibitor-based regimens and such change, if needed, should occur at least 4 weeks prior to cessation of oral antiretroviral therapy;
  5. Subject has two or more potential alternative antiretroviral drug options available;
  6. Plasma HIV-1 RNA <50 copies/mL at Screening Visit as determined by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR);
  7. No documented detectable viral loads (HIV-1 RNA > 50 copies/mL) within the last 24 weeks prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA <400 copies/mL) can be considered, although the preceding and following HIV-1 RNA measurements should be <50 copies/mL;
  8. CD4 cell count of >300 cells/mm3 at Screening Visit;

  9. Laboratory values at Screening:

     1. Absolute neutrophil count (ANC) ≥750/ mm3;
     2. Hemoglobin (Hb) ≥10.5 gm/dL (male) or ≥9.5 gm/dL (female);
     3. Platelets ≥75,000 /mm3;
     4. Serum alanine transaminase (SGPT/ALT) <1.25 x upper limit of normal (ULN);
     5. Serum aspartate transaminase (SGOT/AST) <1.25 x ULN;
     6. Serum total bilirubin within normal range; and
     7. Creatinine ≤1.5 x ULN.
  10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator;
  11. Both male and female subjects and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized or who do not have sex with women). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug;
  12. Willing and able to participate in all aspects of the study, including use of intravenous medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.

Exclusion Criteria:

• Potential subjects meeting any of the following criteria will be excluded from enrollment.

  1. Any active infection or malignancy requiring acute therapy;
  2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg);
  3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening;
  4. Grade 4 DAIDS laboratory abnormality;
  5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study;
  6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose;
  7. Any vaccination within 2 weeks prior to the first study dose;
  8. Subjects weighing <35kg;
  9. History of anaphylaxis to any oral or parenteral drugs;
  10. Use of any fusion inhibitors and broadly neutralizing monoclonal antibody prior to the Screening Visit;
  11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit;
  12. Any known allergy or antibodies to the study drug or excipients;

  13. Treatment with any of the following:

      1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit;
      2. Immunosuppressants or immunomodulating agents within 60 days prior to the screening visit; or

      3. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:

         • Subjects on inhaled, nasal, or topical steroids will not be excluded.
  14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Contacts and Locations

Contacts

Contact: Cheng Yao, M.D.; (+86)025-69648387; yaocheng@frontierbiotech.com

Locations

United States, California

ABT-3BNC117_201 Investigational Site; Recruiting

Palm Springs, California, United States, 92262

ABT-3BNC117_201 Investigational Site; Recruiting

San Francisco, California, United States, 94115

United States, Florida

ABT-3BNC117_201 Investigational Site; Recruiting

Fort Pierce, Florida, United States, 34982

ABT-3BNC117_201 Investigational Site; Recruiting

Hialeah, Florida, United States, 33016

ABT-3BNC117_201 Investigational Site; Recruiting

Orlando, Florida, United States, 32803

United States, Georgia

ABT-3BNC117_201 Investigational Site; Recruiting

Atlanta, Georgia, United States, 30312

United States, New York

ABT-3BNC117_201 Investigational Site; Recruiting

New York, New York, United States, 10029

Sponsors and Collaborators

Frontier Biotechnologies Inc.

Investigators

• Study Director: Frontier clinical team; Frontier Biotechnologies Inc.

More Information

• Responsible Party: Frontier Biotechnologies Inc.
• ClinicalTrials.gov Identifier: NCT03719664
• Other Study ID Numbers: ABT-3BNC117_201
• First Posted: October 25, 2018
• Last Update Posted: September 29, 2021
• Last Verified: September 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Frontier Biotechnologies Inc.:

HIV-1; 3BNC117; Albuvirtide; Broadly neutralizing antibody; Long-Acting HIV-1 Fusion Inhibitor

Additional relevant MeSH terms:

Infections